Selinexor with BEAM before stem cell transplant for MYC-positive DLBCL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests adding the drug selinexor to a standard high-dose chemotherapy regimen (BEAM) before an autologous stem cell transplant for people with MYC-positive diffuse large B-cell lymphoma that has returned or not responded to prior treatments. The goal is to see if this combination is safe and effective in preparing the body for the transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with diffuse large B-cell lymphoma (DLBCL) that has come back or not fully responded after at least two lines of treatment, and you are in partial or complete remission now.
- Your tumor tissue tested positive for MYC (a protein that can make the cancer grow faster).
- You are between 18 and 65 years old.
- You are generally able to care for yourself (ECOG score 0-2).
- Your major organs (liver, kidneys, heart, blood) are functioning well enough, based on standard blood tests and heart checks.
- You have never had a stem cell transplant using your own cells before, and you have not been treated with selinexor before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding selinexor to the standard R-CHOP chemotherapy for people with a specific type of diffuse large B-cell lymphoma (DLBCL) that has a TP53 mutation. The goal is to see if this combination works better as the first treatment.
This trial studies the best way to use an early (frontline) stem cell transplant for high-risk, CD20-positive diffuse large B-cell lymphoma (DLBCL). It aims to improve outcomes by comparing treatment approaches designed for people with a higher risk score.
This trial tests a new drug (zanubrutinib) combined with a strong chemotherapy regimen (BEAM) before a stem cell transplant. The goal is to see if this combination can help people whose lymphoma has come back or not responded to previous treatments.
This Phase 3 study compares two chemotherapy schedules (Chi-BEAM vs BEAM) given before an autologous stem cell transplant to treat newly diagnosed peripheral T-cell lymphoma that responded to first-line treatment. If you fit the lab and heart/lung requirements, it may offer access to a new treatment approach designed to improve outcomes.
This trial tests adding a targeted drug called pirtobrutinib to a standard high-dose chemotherapy regimen before a stem cell transplant. It aims to improve outcomes for people with diffuse large B-cell lymphoma that has come back or not responded to previous treatments.
This trial tests two drugs, glofitamab and selinexor, for patients with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to at least two previous treatments. The goal is to see if this combination can help control the cancer.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.